ArticleDiabetes technology & therapeutics2024
Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod
Article in Diabetes technology & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Extended Use of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 1 Diabetes: 12-Month Extension of a Randomized Controlled Trial.Endocrinology, diabetes & metabolism · 2026Trial
- Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel-group clinical trial sub-study.Diabetes, obesity & metabolism · 2026Trial
- Trial
- Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes.Diabetes, obesity & metabolism · 2024Trial
- Trial
- Eighteen-Month Hybrid Closed-Loop Use in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Trial.Diabetes care · 2024Trial
- Long-term effectiveness of automated insulin delivery in young people with type 1 diabetes: a meta-analysis.Diabetology & metabolic syndrome · 2026Article
- Transitioning to Omnipod 5Biomedicines · 2026Article
- Inpatient Use of Automated Insulin Delivery Systems.Journal of diabetes science and technology · 2026Review
- Long-term efficacy and safety of Control-IQ technology in younger children with type 1 diabetes in Italy (2020-2023): a longitudinal multicentre real-world study.EClinicalMedicine · 2026Article
- Ethnicity and socioeconomic status do not influence glycaemic outcomes of a tubeless hybrid closed-loop system (Omnipod® 5) in adults with type 1 diabetes.Diabetes, obesity & metabolism · 2025Observational
- Omnipod 5 in children and adolescents with type 1 diabetes: Improved outcomes with fewer boluses.Diabetes, obesity & metabolism · 2025Article
- Registration and Real-Life Studies on Automated Insulin Delivery Systems.Journal of diabetes science and technology · 2025Review
- Does the OP5 Automated Insulin Delivery System Close the Gap in Glycemic Control Between White and Black Youth with Type 1 Diabetes?Diabetes technology & therapeutics · 2025Article
- Real-world glycemic outcomes of a tubeless automated insulin delivery system: a single-center observational study in Italy.Frontiers in endocrinology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 11 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.